Completed PHASE2 INTERVENTIONAL 1-arm NCT00142480

Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer

Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Biliary Tract and Gallbladder Cancer

Sponsor: Beth Israel Deaconess Medical Center

Conditions Biliary Tract Cancer Gallbladder Adenocarcinoma

Interventions Bevacizumab Capecitabine Oxaliplatin Radiation therapy

Updated 7 times since 2017 Last updated: Apr 23, 2018 Started: Dec 31, 2004 Primary completion: Jul 31, 2007 Completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Biliary Tract Cancer and Gallbladder Adenocarcinoma, this trial is completed. The trial is conducted by Beth Israel Deaconess Medical Center and has accumulated 7 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
May 2018 — Jun 2018 [monthly]

Completed PHASE2

Status: Unknown Status → Completed

▶ Show 2 earlier versions

Feb 2017 — May 2018 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Genentech, Inc.
Hoffmann-La Roche
Massachusetts General Hospital
Sanofi-Synthelabo

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States